News Seven future blockbuster drugs to look out for in 2019 AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023.
Oncology ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny ASCO is always an interesting show for KITE Therapeutics, the Gilead Sciences subsidiary focused on cell therapy.
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.